Mink Therapeutics Inc banner

Mink Therapeutics Inc
NASDAQ:INKT

Watchlist Manager
Mink Therapeutics Inc Logo
Mink Therapeutics Inc
NASDAQ:INKT
Watchlist
Price: 11.14 USD 1.74% Market Closed
Market Cap: $55.4m

Mink Therapeutics Inc
Other Non-Cash Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mink Therapeutics Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Mink Therapeutics Inc
NASDAQ:INKT
Other Non-Cash Items
$3.1m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$9.5B
CAGR 3-Years
12%
CAGR 5-Years
2%
CAGR 10-Years
25%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
$2.5B
CAGR 3-Years
-24%
CAGR 5-Years
-21%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$1.2B
CAGR 3-Years
26%
CAGR 5-Years
41%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$183.1m
CAGR 3-Years
-48%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
No Stocks Found

Mink Therapeutics Inc
Glance View

Market Cap
55.4m USD
Industry
Biotechnology

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 33 full-time employees. The company went IPO on 2021-10-15. The firm is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The firm offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.

INKT Intrinsic Value
Not Available

See Also

What is Mink Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
3.6m USD

Based on the financial report for Dec 31, 2023, Mink Therapeutics Inc's Other Non-Cash Items amounts to 3.6m USD.

What is Mink Therapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
-16%

Over the last year, the Other Non-Cash Items growth was 1 397%. The average annual Other Non-Cash Items growth rates for Mink Therapeutics Inc have been -16% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett